Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FCER2 | P06734 | 2/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 2/20 | 0.49 |
| ▸ | MMP9 | P14780 | 2/20 | 0.49 |
| ▸ | MMP8 | P22894 | 2/20 | 0.49 |
| ▸ | REN | P00797 | 1/20 | 0.49 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.48 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.48 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.47 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20816950 | 1.00 | FCER2 (0.52) | FCER2CTSBMMP2MMP9MMP8 | |
| SCHEMBL20816946 | 1.00 | FCER2 (0.52) | FCER2CTSBMMP2MMP9MMP8 | |
| SCHEMBL20816587 | 0.94 | OPRD1 (0.51) | FCER2CTSBMMP2MMP9MMP8 | |
| SCHEMBL20816584 | 0.94 | OPRD1 (0.51) | FCER2CTSBMMP2MMP9MMP8 | |
| SCHEMBL20816782 | 0.92 | OPRD1 (0.50) | FCER2CTSBMMP2MMP9MMP8 | |
| SCHEMBL20816787 | 0.92 | OPRD1 (0.50) | FCER2CTSBMMP2MMP9MMP8 | |
| SCHEMBL20816577 | 0.92 | OPRD1 (0.50) | FCER2CTSBMMP2MMP9MMP8 | |
| SCHEMBL20816847 | 0.90 | CTSB (0.50) | FCER2CTSBMMP2MMP9MMP8 | |
| SCHEMBL20816610 | 0.90 | CTSB (0.50) | FCER2CTSBMMP2MMP9MMP8 | |
| SCHEMBL20827984 | 0.90 | CAPN1 (0.62) | CTSBRENCAPN1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190085024-A1 | Alpha-Ketoamide Inhibitors Of Cysteine Proteases | Phelix Therapeutics (US) | 2019-03-21 | — | — | US | claimed |
| US-20190085024-A1 | Alpha-Ketoamide Inhibitors Of Cysteine Proteases | Phelix Therapeutics (US) | 2019-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190085024-A1 | Alpha-Ketoamide Inhibitors Of Cysteine Proteases | CTSS, CTSB, CTSL | FCER2 4241/4885CTSB 2/4885MMP2 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.